SIRPA and neoplasm: Anti-cancer treatments (e.g., immunotherapy) by intervening the binding affinity of CD47 to SIRPα contribute to the adaptive immune response and tumour cells phagocytosis (Ring et al., 2017; Weiskopf, 2017; Zhang et al., 2020).